Keywords: Elan, Biogen Idec, Third-quarter 2010 financial results, Tysabri

Elan sees 3rd-qtr 2010 revenues slip 2%, and posts $43.6 million net loss; Tysabri partner Biogen Idec exceeds forecasts

Article | 28 October 2010

Print This

Irish drugmaker Elan Corp (NYSE: ELN) said it made a net loss of $43.6 million for the three months to September 2010 ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in